Regeneron Pharmaceuticals, Inc.
NASDAQ:REGNBiotechnology
-$5.45 today
- Market cap
- $97.80B
- Beta
- 0.24
- P/E (TTM)
- 14.2
- EPS (TTM)
- $42.53
- Dividend yield
- 0.60%
Volume 0.70M
Average 0.91M
REGN Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Regeneron Pharmaceuticals, Inc.NASDAQ: REGN
Retained Earnings · Q2 FY2026 · quarter ended Jun 2026
Retained earnings rises 11.7% from a year ago
Retained earnings stood at $37.62B at the end of Q2 FY2026, up 11.7% from a year earlier and up 3.3% from the prior quarter. Over 3 fiscal years it compounded at +15.4% a year.
Context
- Retained earnings amounted to 90.2% of total assets at the end of Q2 FY2026, up 2.0 pp from a year earlier.
- Retained earnings increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps rising in the next quarterly balance sheet after a +11.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- 35.8B USD
- Year-over-year change
- +13.0%
- 4-year CAGR
- +17.2%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 35.8B | +13.0% |
| FY2024 | 2024-12-31 | 31.67B | +16.2% |
| FY2023 | 2023-12-31 | 27.26B | +17.0% |
| FY2022 | 2022-12-31 | 23.31B | +22.9% |
| FY2021 | 2021-12-31 | 18.97B | — |
Retained Earnings vs competitors
How REGN compares with its peers on the latest reported figures
- REGN's Jun 2026 retained earnings of $37.62B is the 2nd highest of the 9 companies compared; the peer median is $3.31B.
- Its year-over-year change of +11.7% is the 4th highest of 9, against a peer median of -0.2%.
- Retained earnings amounts to 90.2% of total assets for REGN, versus a peer median of 33.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $39.65B | -4.5% | -11.0% | 32.5% | |
| Jun 2026 | $37.62B | +11.7% | +15.4% | 90.2% | |
| Jun 2026 | $20.97B | +4.1% | +7.7% | 65.4% | |
| Sep 2026 | $14.04B | +71.0% | — | 11.7% | |
| Jun 2026 | $4.42B | +22.9% | -34.9% | 35.3% | |
| Jun 2026 | $2.2B | -80.6% | -4.3% | 4.5% | |
| Mar 2026 | -$1.19B | -29.6% | — | 412.8% | |
| Mar 2026 | -$1.25B | -30.4% | — | 170.0% | |
| Jun 2026 | -$22.28B | +13.4% | — | 23.3% | |
| Peer median (excluding REGN) | $3.31B | -0.2% | -7.7% | 33.9% | |
Competitors are the stored peer set for REGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 2.89B | 3.11B | 2.73B | 2.49B | 3.12B |
| Short-term Investments | 2.81B | 4.64B | 8.11B | 6.52B | 5.49B |
| Net Receivables | 6.04B | 5.33B | 5.67B | 6.21B | 5.74B |
| Inventory | 1.95B | 2.4B | 2.58B | 3.09B | 3.2B |
| Other Current Assets | 0 | 0 | 386.6M | 349.2M | 474.8M |
| Total Current Assets | 14.01B | 15.88B | 19.48B | 18.66B | 18.02B |
| Property, Plant & Equipment (Net) | 3.48B | 3.76B | 4.15B | 4.6B | 5.12B |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 6.7M | 915.5M | 1.04B | 1.15B | 1.26B |
| Long-term Investments | 6.84B | 6.59B | 5.4B | 8.9B | 10.26B |
| Tax Assets | 876.9M | 1.72B | 2.58B | 3.31B | 4.08B |
| Other Non-current Assets | 216.1M | 336.4M | 444.1M | 1.14B | 1.82B |
| Total Non-current Assets | 11.42B | 13.33B | 13.6B | 19.1B | 22.54B |
| Total Assets | 25.43B | 29.21B | 33.08B | 37.76B | 40.56B |
| Account Payables | 564M | 589.2M | 606.6M | 789.5M | 939M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 326.3M | 300K | 0 | 213.2M | 0 |
| Deferred Revenue | 442M | 477.9M | 458.9M | 627.7M | 553M |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | 3.93B | 3.14B | 3.42B | 3.94B | 4.37B |
| Long-term Debt | 1.98B | 1.98B | 1.98B | 1.98B | 1.99B |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 73.3M | 69.8M | 126.7M | 185.7M | 208.7M |
| Other Non-current Liabilities | 680.2M | 638M | 854.1M | 1.57B | 2.02B |
| Total Non-current Liabilities | 2.73B | 3.41B | 3.68B | 4.46B | 4.93B |
| Total Liabilities | 6.67B | 6.55B | 7.11B | 8.41B | 9.3B |
| Common Stock | 100K | 100K | 100K | 100K | 100K |
| Retained Earnings | 18.97B | 23.31B | 27.26B | 31.67B | 35.8B |
| Accumulated OCI | (26.2M) | (238.8M) | (80.9M) | (7.9M) | 77.5M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 18.77B | 22.66B | 25.97B | 29.35B | 31.26B |
| Total Debt | 2.7B | 2.7B | 2.7B | 2.7B | 2.71B |
| Net Debt | (185.9M) | (404.5M) | (27.1M) | 216.2M | (412.2M) |
Regeneron Pharmaceuticals, Inc.
NASDAQ:REGN
Intrinsic Alpha fair value
Locked
Current Price
$945.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.